Mustang Bio, Inc. (MBIO) Stock Analysis & Investment Frameworks
Mustang Bio, Inc. (MBIO) stock analysis on Invetso. Review Mustang Bio, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Mustang Bio, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Mustang Bio, Inc. Key Financial Metrics
- Market Cap: $2.76M
- Revenue: $N/A
- ROE: -34.23%
- ROIC: -45.77%
- Dividend Yield: N/A
About Mustang Bio, Inc.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Mustang Bio, Inc. Investment Frameworks
Invetso analyzes Mustang Bio, Inc. (MBIO) across the following frameworks:
- Mustang Bio, Inc. 10Y Growth Potential
- Mustang Bio, Inc. Scenario Analysis
- Mustang Bio, Inc. Risks & Opportunities
- Mustang Bio, Inc. Economic Moat
- Mustang Bio, Inc. Business Model
- Mustang Bio, Inc. Management
- Mustang Bio, Inc. SWOT Analysis
- Mustang Bio, Inc. Porter's 5 Forces
- Mustang Bio, Inc. PESTLE Analysis
- Mustang Bio, Inc. ESG Analysis